Array BioPharma (NASDAQ:ARRY)

ten dollars

Eight Analyst Stocks to Buy Under $10 for Big Upside

Stocks hit an all-time high this past week. What is puzzling now is that investors and traders keep hearing that the raging bull market is over, and that this has ...
Read Full Story »
$5

Eight Biotech Stocks Trading Near $5 With Huge Upside Potential

Often when a strong sell-off hits the stock market, the first stocks to go are the big momentum stocks that hedge funds often chase for performance and alpha. Right behind ...
Read Full Story »
biotech

Jefferies Top Biotech Stocks to Buy

The world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can ...
Read Full Story »
biotech

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

Investors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the ...
Read Full Story »

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) ...
Read Full Story »

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

It is now getting close to the middle of May, and that means one thing for biotech investors.  The king of biotech and pharma events is about to take place.  ...
Read Full Story »

Mid-day Movers (IPSU, DMND, TSL, ARRY, AONE)

At about noon, the three major equity indexes have all turned positive after an up-and-down morning. The DJIA is up about 11 points at about 12,896, the Nasdaq is ;up ...
Read Full Story »

Top Active Trader Alert Stocks (ACTL, AIB, ARRY, GTSI, ISLN, MSFT, NBG)

Active traders and day traders have many stocks to choose from this morning.  We are tracking moves in Actel Corporation (NASDAQ: ACTL), Allied Irish Banks plc (NYSE: AIB), Array BioPharma, ...
Read Full Story »

Top Analyst Upgrades and Downgrades (ADBE, AA, AAPL, ARRY, CHK, CMG, EMC, HOV, MTG, SNDK, SPG)

These are some of the key research calls from this Thursday's analyst upgrades, downgrades, and initiations seen from Wall Street research calls: Adobe Systems Inc. (NASDAQ: ADBE) Reiterated Buy but ...
Read Full Story »

BioHealth Business Daily (AGEN, ARRY, GENZ, GILD, HGSI, NPSP, QLTI, RPTP, STEM, BBH, IBB, PBE)

Today's version of the BioHealth Business Daily is rather different as we have a big disappointment from one of the top biotech operations in the world.  BioHealth stocks moving on ...
Read Full Story »

Top Day Trader Alerts (GS, MGM, IBM, HGSI, ARRY)

These are this morning's top day trader and active trader alerts.  We have links on each where appropriate with much more detail on the news, volume, price change and analysis ...
Read Full Story »

Array Biopharma (ARRY) Gets Lucky

Small biopharma stocks sometimes have that one big day, the day that there investors wait for. Array Biopharma (NASDAQ:ARRY) moved higher by 30% early in the day to $3.11. The ...
Read Full Story »

Top Day Trader Alerts (WFC, JASO, LIMS, ARRY, GILD)

This morning's top day trader and active trader alerts are below with links to VSInvestor.com on each stock story with more detailed data and analysis: Wells Fargo & Co. (NYSE: ...
Read Full Story »
bull-and-bear-image

Top Day Trader Alerts (ARRY, HGSI, MTXX, NVLS, FNM)

Because this is a Friday ahead of a 3-day weekend and because this is Labor Day, the "volume spikes" and the relative trading will be more muted than most trading ...
Read Full Story »
biotech

The Next Blockbuster Drugs: A $170 Billion Opportunity

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential ...
Read Full Story »